Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Evaluating the Combination of the Atezolizumab (TECENTRIQ) and Niraparib (ZEJULA) in Patients with Metastatic Bladder Cancer.

Next Previous
Trial Profile

A Trial Evaluating the Combination of the Atezolizumab (TECENTRIQ) and Niraparib (ZEJULA) in Patients with Metastatic Bladder Cancer.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Niraparib (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech

Most Recent Events

  • 28 Feb 2018 New trial record
  • 26 Feb 2018 According to a TESARO media release, this trial will be conducted by Genentech and is expected to begin mid-2018.
  • 26 Feb 2018 According to a TESARO media release, the company announced that it has entered into a clinical collaboration with Genentech (a member of the Roche Group) to evaluate the combination of Atezolizumab and Niraparib in patients with metastatic bladder cancer.The collaboration includes testing this experimental combination in MORPHEUS which is a phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top